Y-mAbs Therapeutics (YMAB) PT Lowered to $67 at Wedbush, Following Earnings
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Wedbush analyst David Nierengarten lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $67.00 (from $71.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Western Alliance Bancorporation (WAL) PT Raised to $125 at Wedbush, Following Earnings
- Industrial Bank of Korea (024110:KS) PT Raised to KRW10,000 at Morgan Stanley
- Localiza Rent a Car S.A. (RENT3:BZ) (LZRFY) PT Lowered to R$67 at Morgan Stanley